BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- European shares subdued as surging crude sharpens focus on ECB rate path
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves
August 2, 2016 11:56 AM EDTOn Monday, CVS Health (NYSE: CVS) released its 2017 Standard Formulary Exclusion List and Express Scripts (NASDAQ: ESRX) released its 2017 National Preferred Formulary exclusion list.
Below is a summary of analyst commentary around the list changes:
CVS 2017 Standard Formulary Exclusion List:
Barclays analyst Eric Percher said most notably, CVS signaled aggressively on biosimilars, replacing Neupogen with Zarxio (limited impact under the pharmacy benefit) and Lantus with Basaglar for 2017 (significant impact under the pharmacy benefit)
Percher noted a therapeutics focus on Oncology,... More
Horizon Pharma (HZNP): Contracting Activity Picking Up - Mizuho
August 2, 2016 9:51 AM EDTMizuho Securities analyst, Irina Koffler, reiterated her Outperform rating on shares of Horizon Pharma (NASDAQ: HZNP). The analyst believes that contracting activity is likely to pick up in the back half of the year. Yesterday during market hours, the release of the 2017 Express Scripts exclusion list, followed by the CVS/Caremark... More
Horizon Pharma (HZNP) Says DUEXIS and VIMOVO Will be Covered by CVS/Caremark
August 2, 2016 7:13 AM EDTHorizon Pharma (NASDAQ: HZNP) disclosed the following on Tuesday morning:
Item 7.01 Regulation FD Disclosure.
Horizon Pharma has secured covered status for DUEXIS and VIMOVO with CVS/Caremark. The Company has been informed that beginning January 1, 2017, DUEXIS and VIMOVO will be removed from the CVS/Caremark exclusion list.
... More